problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl13441problendo-13441Research ArticleКлиническая эндокринологияClinical endocrinologyНекласические гормоны из семейства факторов роста фибробластовNon-classical hormones from the fibroblast growth factor familyhttps://orcid.org/0000-0001-7055-2407ГронскаяС. А.GronskaiaS. A.

Гронская Софья Александровна

117036, Москва, ул. Дмитрия Ульянова, д. 11

Sofya A. Gronskaia – MD.

11 Dm. Ulyanova street, 117036 Moscow

sofyaants@gmail.comhttps://orcid.org/0000-0003-3628-2102РусяеваН. В.RusyaevaN. V.

Русяева Надежда Владимировна – аспирант.

Москва

Nadezhda V. Rusyaeva - MD, PhD student.

Moscow

nadshul@gmail.comhttps://orcid.org/0000-0002-6674-6441БелаяЖ. Е.BelayaZh. E.

Белая Жанна Евгеньевна - д.м.н., профессор.

Москва

Zhanna E. Belaya - MD, PhD, Professor.

Moscow

jannabelaya@gmail.comhttps://orcid.org/0000-0002-5634-7877МельниченкоГ. А.MelnichenkoG. A.

Мельниченко Галина Афанасьевна - академик РАН, д.м.н., профессор.

Москва

Galina A. Melnichenko - MD, PhD, Professor.

Moscow

teofrast2000@mail.ruНаучный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation2024041120247052333Copyright © Гронская С.А., Русяева Н.В., Белая Ж.Е., Мельниченко Г.А., 20242024Гронская С.А., Русяева Н.В., Белая Ж.Е., Мельниченко Г.А.Gronskaia S.A., Rusyaeva N.V., Belaya Z.E., Melnichenko G.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/13441

Факторы роста фибробластов (ФРФ) — это группа сигнальных молекул, получивших свое название благодаря положительному влиянию на рост и размножение фибробластов. ФРФ оказывают свои эффекты преимущественно локально в тканях. Однако ФРФ 19, ФРФ 21 и ФРФ 23 секретируются в кровь и оказывают влияние на отдаленные органы и ткани, поэтому их можно классифицирвоать как неклассические гормоны. Биологическая роль ФРФ многообразна и зависит в большей степени от рецепторов и кофакторов, участвующих в передаче сигнала. ФРФ 19 и ФРФ 21 во­влечены в обмен глюкозы и липидов, а ФРФ 23 известен своим влиянием на обмен фосфора. ФРФ являются перспективными мишенями для разработки лекарственных средств. В настоящем обзоре суммируются современные знания о биологических эффектах неклассических гормонов из семейства ФРФ и потенциальные возможности их применения в качестве терапевтических мишеней.

Fibroblast growth factors (FGFs) are a group of signaling molecules named for their ability to promote the growth and proliferation of fibroblasts and various other cell types. Typically, FGFs exert their effects locally by binding to receptors within the tissues where they are synthesized. However, certain members of this family, such as FGF 19, FGF 21, and FGF 23, diverge from this pattern. Following synthesis, these FGFs enter the bloodstream and act on distant organs and tissues by binding to their receptors and associated cofactors, thereby classified as non-classical hormones within the FGF family.

The biological functions of FGFs are diverse and contingent upon the specific receptors and cofactors involved in their signaling pathways. For instance, FGF 19 and FGF 21 play crucial roles in regulating glucose and lipid metabolism, whereas FGF 23 primarily influences phosphorus metabolism. Given their varied roles, FGFs present promising targets for therapeutic interventions and drug development.

This review aims to consolidate current understanding of FGF family hormones, elucidating their biological impacts and exploring their potential applications as therapeutic targets.

фактор роста фибробластовФРФ 23ФРФ 19ФРФ 21fibroblast growth factorFGF23FGF19FGF21Государственное задание №124020700097-8ReferencesHui Q, Jin Z, Li X, Liu C, Wang X. FGF Family: From Drug Development to Clinical Application. Int J Mol Sci. 2018;19(7):1875. doi: https://doi.org/10.3390/ijms19071875Hui Q, Jin Z, Li X, Liu C, Wang X. FGF Family: From Drug Development to Clinical Application. Int J Mol Sci. 2018;19(7):1875. doi: https://doi.org/10.3390/ijms19071875Angelin B, Larsson TE, Rudling M. Circulating Fibroblast Growth Factors as Metabolic Regulators—A Critical Appraisal. Cell Metab. 2012;16(6):693-705. doi: https://doi.org/10.1016/j.cmet.2012.11.001Angelin B, Larsson TE, Rudling M. Circulating Fibroblast Growth Factors as Metabolic Regulators—A Critical Appraisal. Cell Metab. 2012;16(6):693-705. doi: https://doi.org/10.1016/j.cmet.2012.11.001Somm E, Jornayvaz FR. Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives. Endocr Rev. 2018;39(6):960-989. doi: https://doi.org/10.1210/er.2018-00134Somm E, Jornayvaz FR. Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives. Endocr Rev. 2018;39(6):960-989. doi: https://doi.org/10.1210/er.2018-00134Zhao Y, Meng C, Wang Y, et al. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes. Am J Physiol-Endocrinol Metab. 2016;310(4):E289-E300. doi: https://doi.org/10.1152/ajpendo.00356.2015Zhao Y, Meng C, Wang Y, et al. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes. Am J Physiol-Endocrinol Metab. 2016;310(4):E289-E300. doi: https://doi.org/10.1152/ajpendo.00356.2015Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y, Nabeshima Y ichi. Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho. J Clin Invest. 2005;115(8):2202-2208. doi: https://doi.org/10.1172/JCI23076Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y, Nabeshima Y ichi. Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho. J Clin Invest. 2005;115(8):2202-2208. doi: https://doi.org/10.1172/JCI23076Kir S, Beddow SA, Samuel VT, et al. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science. 2011;331(6024):1621-1624. doi: https://doi.org/10.1126/science.1198363Kir S, Beddow SA, Samuel VT, et al. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science. 2011;331(6024):1621-1624. doi: https://doi.org/10.1126/science.1198363Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway. Cell Metab. 2011;13(6):729-738. doi: https://doi.org/10.1016/j.cmet.2011.03.019Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway. Cell Metab. 2011;13(6):729-738. doi: https://doi.org/10.1016/j.cmet.2011.03.019Gómez-Ambrosi J, Gallego-Escuredo JM, Catalán V, et al. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clin Nutr. 2017;36(3):861-868. doi: https://doi.org/10.1016/j.clnu.2016.04.027Gómez-Ambrosi J, Gallego-Escuredo JM, Catalán V, et al. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clin Nutr. 2017;36(3):861-868. doi: https://doi.org/10.1016/j.clnu.2016.04.027Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis. Nat Commun. 2015;6(1):6980. doi: https://doi.org/10.1038/ncomms7980Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis. Nat Commun. 2015;6(1):6980. doi: https://doi.org/10.1038/ncomms7980Benoit B, Meugnier E, Castelli M, et al. Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat Med. 2017;23(8):990-996. doi: https://doi.org/10.1038/nm.4363Benoit B, Meugnier E, Castelli M, et al. Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat Med. 2017;23(8):990-996. doi: https://doi.org/10.1038/nm.4363Guo A, Li K, Tian H, et al. FGF19 protects skeletal muscle against obesity‐induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT‐1/PGC‐α pathway. J Cell Mol Med. 2021;25(7):3585-3600. doi: https://doi.org/10.1111/jcmm.16448Guo A, Li K, Tian H, et al. FGF19 protects skeletal muscle against obesity‐induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT‐1/PGC‐α pathway. J Cell Mol Med. 2021;25(7):3585-3600. doi: https://doi.org/10.1111/jcmm.16448Guo A, Li K, Tian HC, Tao BL, Xiao Q, Jiang DM. FGF19 protects against obesity-induced bone loss by promoting osteogenic differentiation. Biomed Pharmacother. 2022;146:112524. doi: https://doi.org/10.1016/j.biopha.2021.112524Guo A, Li K, Tian HC, Tao BL, Xiao Q, Jiang DM. FGF19 protects against obesity-induced bone loss by promoting osteogenic differentiation. Biomed Pharmacother. 2022;146:112524. doi: https://doi.org/10.1016/j.biopha.2021.112524Yamamoto S, Koyama D, Igarashi R, et al. Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients. Intern Med. 2020;59(3):345-355. doi: https://doi.org/10.2169/internalmedicine.3597-19Yamamoto S, Koyama D, Igarashi R, et al. Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients. Intern Med. 2020;59(3):345-355. doi: https://doi.org/10.2169/internalmedicine.3597-19Padrissa-Altés S, Bachofner M, Bogorad RL, et al. Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice. Gut. 2015;64(9):1444-1453. doi: https://doi.org/10.1136/gutjnl-2014-307874Padrissa-Altés S, Bachofner M, Bogorad RL, et al. Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice. Gut. 2015;64(9):1444-1453. doi: https://doi.org/10.1136/gutjnl-2014-307874Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta BBA - Gene Struct Expr. 2000;1492(1):203-206. doi: https://doi.org/10.1016/S0167-4781(00)00067-1Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta BBA - Gene Struct Expr. 2000;1492(1):203-206. doi: https://doi.org/10.1016/S0167-4781(00)00067-1Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol. 2022;13:1089214. doi: https://doi.org/10.3389/fphar.2022.1089214Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol. 2022;13:1089214. doi: https://doi.org/10.3389/fphar.2022.1089214Szczepańska E, Gietka-Czernel M. FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. Horm Metab Res. 2022;54(04):203-211. doi: https://doi.org/10.1055/a-1778-4159Szczepańska E, Gietka-Czernel M. FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. Horm Metab Res. 2022;54(04):203-211. doi: https://doi.org/10.1055/a-1778-4159Minard AY, Tan SX, Yang P, et al. mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep. 2016;17(1):29-36. doi: https://doi.org/10.1016/j.celrep.2016.08.086Minard AY, Tan SX, Yang P, et al. mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep. 2016;17(1):29-36. doi: https://doi.org/10.1016/j.celrep.2016.08.086Díaz-Delfín J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-α Represses β-Klotho Expression and Impairs FGF21 Action in Adipose Cells: Involvement of JNK1 in the FGF21 Pathway. Endocrinology. 2012;153(9):4238-4245. doi: https://doi.org/10.1210/en.2012-1193Díaz-Delfín J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-α Represses β-Klotho Expression and Impairs FGF21 Action in Adipose Cells: Involvement of JNK1 in the FGF21 Pathway. Endocrinology. 2012;153(9):4238-4245. doi: https://doi.org/10.1210/en.2012-1193Wang L, Mazagova M, Pan C, et al. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proc Natl Acad Sci. 2019;116(30):15184-15193. doi: https://doi.org/10.1073/pnas.1904360116Wang L, Mazagova M, Pan C, et al. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proc Natl Acad Sci. 2019;116(30):15184-15193. doi: https://doi.org/10.1073/pnas.1904360116Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654-667. doi: https://doi.org/10.1038/s41574-020-0386-0Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654-667. doi: https://doi.org/10.1038/s41574-020-0386-0Frayling TM, Beaumont RN, Jones SE, et al. A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. Cell Rep. 2018;23(2):327-336. doi: https://doi.org/10.1016/j.celrep.2018.03.070Frayling TM, Beaumont RN, Jones SE, et al. A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. Cell Rep. 2018;23(2):327-336. doi: https://doi.org/10.1016/j.celrep.2018.03.070Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab. 2015;4(1):51-57. doi: https://doi.org/10.1016/j.molmet.2014.09.008Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab. 2015;4(1):51-57. doi: https://doi.org/10.1016/j.molmet.2014.09.008Yilmaz U, Tekin S, Demir M, Cigremis Y, Sandal S. Effects of central FGF21 infusion on the hypothalamus–pituitary–thyroid axis and energy metabolism in rats. J Physiol Sci. 2018;68(6):781-788. doi: https://doi.org/10.1007/s12576-018-0595-7Yilmaz U, Tekin S, Demir M, Cigremis Y, Sandal S. Effects of central FGF21 infusion on the hypothalamus–pituitary–thyroid axis and energy metabolism in rats. J Physiol Sci. 2018;68(6):781-788. doi: https://doi.org/10.1007/s12576-018-0595-7Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635. doi: https://doi.org/10.1172/JCI23606Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635. doi: https://doi.org/10.1172/JCI23606BonDurant LD, Ameka M, Naber MC, et al. FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. Cell Metab. 2017;25(4):935-944.e4. doi: https://doi.org/10.1016/j.cmet.2017.03.005BonDurant LD, Ameka M, Naber MC, et al. FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. Cell Metab. 2017;25(4):935-944.e4. doi: https://doi.org/10.1016/j.cmet.2017.03.005Véniant MM, Hale C, Helmering J, et al. FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice. Siegmund B, ed. PLoS ONE. 2012;7(7):e40164. doi: https://doi.org/10.1371/journal.pone.0040164Véniant MM, Hale C, Helmering J, et al. FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice. Siegmund B, ed. PLoS ONE. 2012;7(7):e40164. doi: https://doi.org/10.1371/journal.pone.0040164Douris N, Stevanovic DM, Fisher FM, et al. Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice. Endocrinology. 2015;156(7):2470-2481. doi: https://doi.org/10.1210/en.2014-2001Douris N, Stevanovic DM, Fisher FM, et al. Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice. Endocrinology. 2015;156(7):2470-2481. doi: https://doi.org/10.1210/en.2014-2001Kwon MM, O’Dwyer SM, Baker RK, Covey SD, Kieffer TJ. FGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1. Cell Rep. 2015;13(8):1521-1527. doi: https://doi.org/10.1016/j.celrep.2015.10.021Kwon MM, O’Dwyer SM, Baker RK, Covey SD, Kieffer TJ. FGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1. Cell Rep. 2015;13(8):1521-1527. doi: https://doi.org/10.1016/j.celrep.2015.10.021Lin Z, Tian H, Lam KSL, et al. Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice. Cell Metab. 2013;17(5):779-789. doi: https://doi.org/10.1016/j.cmet.2013.04.005Lin Z, Tian H, Lam KSL, et al. Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice. Cell Metab. 2013;17(5):779-789. doi: https://doi.org/10.1016/j.cmet.2013.04.005Holland WL, Adams AC, Brozinick JT, et al. An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice. Cell Metab. 2013;17(5):790-797. doi: https://doi.org/10.1016/j.cmet.2013.03.019Holland WL, Adams AC, Brozinick JT, et al. An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice. Cell Metab. 2013;17(5):790-797. doi: https://doi.org/10.1016/j.cmet.2013.03.019Shimizu M, Sato R. Endocrine Fibroblast Growth Factors in Relation to Stress Signaling. Cells. 2022;11(3):505. doi: https://doi.org/10.3390/cells11030505Shimizu M, Sato R. Endocrine Fibroblast Growth Factors in Relation to Stress Signaling. Cells. 2022;11(3):505. doi: https://doi.org/10.3390/cells11030505Tang Y, Zhang M. Fibroblast growth factor 21 and bone homeostasis. Biomed J. 2023;46(4):100548. doi: https://doi.org/10.1016/j.bj.2022.07.002Tang Y, Zhang M. Fibroblast growth factor 21 and bone homeostasis. Biomed J. 2023;46(4):100548. doi: https://doi.org/10.1016/j.bj.2022.07.002Morovat A, Weerasinghe G, Nesbitt V, et al. Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. J Clin Med. 2017;6(8):80. doi: https://doi.org/10.3390/jcm6080080Morovat A, Weerasinghe G, Nesbitt V, et al. Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. J Clin Med. 2017;6(8):80. doi: https://doi.org/10.3390/jcm6080080Charles ED, Neuschwander‐Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity. 2019;27(1):41-49. doi: https://doi.org/10.1002/oby.22344Charles ED, Neuschwander‐Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity. 2019;27(1):41-49. doi: https://doi.org/10.1002/oby.22344Brown EA, Minnich A, Sanyal AJ, et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Rep. 2023;5(4):100661. doi: https://doi.org/10.1016/j.jhepr.2022.100661Brown EA, Minnich A, Sanyal AJ, et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Rep. 2023;5(4):100661. doi: https://doi.org/10.1016/j.jhepr.2022.100661Charoenphandhu N, Suntornsaratoon P, Krishnamra N, et al. Fibroblast growth factor-21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin-resistant rats. J Bone Miner Metab. 2017;35(2):142-149. doi: https://doi.org/10.1007/s00774-016-0745-zCharoenphandhu N, Suntornsaratoon P, Krishnamra N, et al. Fibroblast growth factor-21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin-resistant rats. J Bone Miner Metab. 2017;35(2):142-149. doi: https://doi.org/10.1007/s00774-016-0745-zГронская С.А., Белая Ж.Е., Мельниченко Г.А. ФРФ23-индуцированная остеомаляция опухолевого генеза // Проблемы эндокринологии. — 2022. — Т. 68. — №5. — С. 56-66.. doi: https://doi.org/10.14341/probl13130Gronskaia SA, Belaya ZhE, Melnichenko GA. FGF23 tumor induced osteomalacia. Probl Endocrinol. 2022;68(5):56-66 (In Russ.). doi: https://doi.org/10.14341/probl13130Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol-Ren Physiol. 2010;299(4):F882-F889. doi: https://doi.org/10.1152/ajprenal.00360.2010Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol-Ren Physiol. 2010;299(4):F882-F889. doi: https://doi.org/10.1152/ajprenal.00360.2010Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90(5):985-996. doi: https://doi.org/10.1016/j.kint.2016.05.019Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90(5):985-996. doi: https://doi.org/10.1016/j.kint.2016.05.019Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393-4408. doi: https://doi.org/10.1172/JCI46122Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393-4408. doi: https://doi.org/10.1172/JCI46122Rossaint J, Oehmichen J, Van Aken H, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest. 2016;126(3):962-974. doi: https://doi.org/10.1172/JCI83470Rossaint J, Oehmichen J, Van Aken H, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest. 2016;126(3):962-974. doi: https://doi.org/10.1172/JCI83470Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-1378. doi: https://doi.org/10.1038/ki.2011.47Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-1378. doi: https://doi.org/10.1038/ki.2011.47Roy C, Lejeune S, Slimani A, et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7(5):2494-2507. doi: https://doi.org/10.1002/ehf2.12816Roy C, Lejeune S, Slimani A, et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7(5):2494-2507. doi: https://doi.org/10.1002/ehf2.12816Гронская С.А., Белая Ж.Е., Рожинская Л.Я., et al. Клинические проявления, принципы диагностики и лечения ФРФ23-секретирующих опухолей: результаты наблюдения 40 случаев // Проблемы эндокринологии. — 2023. — Т. 69. — №5. — С. 25-38. doi: https://doi.org/10.14341/probl13221Gronskaia SA, Belaya ZhE, Rozhinskaya LYa, et al. Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases. Probl Endocrinol. 2023;69(5):25-38 (In Russ.). doi: https://doi.org/10.14341/probl13221Гребенникова Т.А., Белая Ж.Е., Цориев Т.Т., Рожинская Л.Я., Мельниченко Г.А. Эндокринная функция костной ткани // Остеопороз и остеопатии. — 2015. — Т. 18. — №1. — С. 28-37. doi: https://doi.org/10.14341/osteo2015128-37Grebennikova TA, Belaya ZE, Tsoriev TT, Rozhinskaya LY, Melnichenko GA. The endocrine function of the bone tissue. Osteoporos Bone Dis. 2015;18(1):28-37 (In Russ.). doi: https://doi.org/10.14341/osteo2015128-37Гребенникова Т.А., Умярова Д.Ш., Слащук К.Ю., и др. Фосфопеническая остеомаляция опухолевого генеза: клинический случай // Остеопороз и остеопатии. — 2018. — Т. 21. — №4. — С. 24-28. doi: https://doi.org/10.14341/osteo10264Grebennikova TA, Umiarova DSh, Slashchuk KY, et al. Tumor-induced osteomalacia: a clinical case report. Osteoporos Bone Dis. 2019;21(4):24-28 (In Russ.). doi: https://doi.org/10.14341/osteo10264Родионова С.С., Снетков А.И., Акиньшина А.Д., и др. Фосфопеническая форма остеомаляции, индуцированная ФРФ23-секретирующей опухолью левой бедренной кости // Научно-практическая ревматология. — 2019. —57. — №6. — С. 708-712. doi: https://doi.org/10.14412/1995-4484-2019-708-712Rodionova SS, Snetkov AI, Akinshina AD, et al. Hypophosphatemic osteomalacia induced by FGF23-secreting tumor of the left femur. Rheumatol Sci Pract. 2019;57(6):708-712 (In Russ.). doi: https://doi.org/10.14412/1995-4484-2019-708-712Овчинников А.Ю., Хон Е.М., Бакотина А.В., Мирошниченко Н.А., Гронская С.А., Белая Ж.Е. ФРФ23-индуцированная остеомаляция опухолевого генеза с локализацией новообразования в барабанной полости // Вестник оториноларингологии. — 2023. — Т. 88. — №6. — С. 91-96. doi: https://doi.org/10.17116/otorino20238806191Ovchinnikov AYu, Khon EM, Bakotina AV, Miroshnichenko NA, Gronskaia SA, Belaya ZhE. FGF23 tumor induced osteomalacia with localization of neoplasm in the tympanic cavity. Vestn Otorinolaringol. 2023;88(6):91 (In Russ.). doi: https://doi.org/10.17116/otorino20238806191Гронская С.А., Голоунина О.О., Буклемишев Ю.В., Хайриева А.В., Дегтярев М.В., Рожинская Л.Я., Белая Ж.Е. Клинический случай фосфопенической формы остеомаляции вследствие паранеопластической секреции метастатического рака предстательной железы // Остеопороз и остеопатии. — 2022. — Т. 25. — №4. — С. 43-51. doi: https://doi.org/10.14341/osteo12948Gronskaya SA, Golounina OO, Buklemishev YuV, et al. A clinical case of phosphopenic osteomalacia due to paraneoplastic secretion of metastatic prostate cance. Osteoporos Bone Dis. 2023;25(4):43-51 (In Russ.). doi: https://doi.org/10.14341/osteo12948Colazo JM, Thompson RC, Covington NV, Dahir KM. An intracranial mass causing tumor-induced osteomalacia (TIO): Rapid and complete resolution of severe osteoporosis after surgical resection. Radiol Case Rep. 2020;15(5):492-497. doi: https://doi.org/10.1016/j.radcr.2020.01.039Colazo JM, Thompson RC, Covington NV, Dahir KM. An intracranial mass causing tumor-induced osteomalacia (TIO): Rapid and complete resolution of severe osteoporosis after surgical resection. Radiol Case Rep. 2020;15(5):492-497. doi: https://doi.org/10.1016/j.radcr.2020.01.039Minisola S, Fukumoto S, Xia W, et al. Tumor-induced Osteomalacia: A Comprehensive Review. Endocr Rev. 2023;44(2):323-353. doi: https://doi.org/10.1210/endrev/bnac026Minisola S, Fukumoto S, Xia W, et al. Tumor-induced Osteomalacia: A Comprehensive Review. Endocr Rev. 2023;44(2):323-353. doi: https://doi.org/10.1210/endrev/bnac026Mansinho A, Ferreira AR, Casimiro S, et al. Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases. Int J Mol Sci. 2019;20(3):695. doi: https://doi.org/10.3390/ijms20030695Mansinho A, Ferreira AR, Casimiro S, et al. Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases. Int J Mol Sci. 2019;20(3):695. doi: https://doi.org/10.3390/ijms20030695Weidner H, Baschant U, Lademann F, et al. Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. JCI Insight. 2020;5(15):e137062. doi: https://doi.org/10.1172/jci.insight.137062Weidner H, Baschant U, Lademann F, et al. Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. JCI Insight. 2020;5(15):e137062. doi: https://doi.org/10.1172/jci.insight.137062Suvannasankha A, Tompkins DR, Edwards DF, et al. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget. 2015;6(23):19647-19660. doi: https://doi.org/10.18632/oncotarget.3794Suvannasankha A, Tompkins DR, Edwards DF, et al. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget. 2015;6(23):19647-19660. doi: https://doi.org/10.18632/oncotarget.3794Cymbaluk-Płoska A, Gargulińska P, Chudecka-Głaz A, Kwiatkowski S, Pius-Sadowska E, Machaliński B. The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients. Diagnostics. 2020;10(6):414. doi: https://doi.org/10.3390/diagnostics10060414Cymbaluk-Płoska A, Gargulińska P, Chudecka-Głaz A, Kwiatkowski S, Pius-Sadowska E, Machaliński B. The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients. Diagnostics. 2020;10(6):414. doi: https://doi.org/10.3390/diagnostics10060414

The authors declare that there are no conflicts of interest present.